



<b>INFORMATION DISCLOSURE CITATION</b> 		ATTY. DOCKET NO. A-68110-1/DJB/JJD	SERIAL NO. 09/637,977
		APPLICANT MURRAY, Richard	
		FILING DATE August 11, 2000	GROUP 1646-1642
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
CY	32	Folkman, "Angiogenesis in cancer, vascular rheumatoid and other disease," <i>Nature Medicine</i> 1(1):27-30 (1995)	
CY	62	Firestein, "Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis," <i>Journal of Clinical Investigation</i> 103(1):3-4 (1999)	
CY	97	Darland and D'Amore, "Blood vessel maturation: vascular development comes of age," <i>Journal of Clinical Investigation</i> 103(2):157-158 (1999)	
CY	82	St. Croix et al., "Genes Expressed in Human Tumor Endothelium," <i>Science</i> 289:1197-1202 (2000)	
CY	9	Kahn et al., "Gene Expression Profiling in an <i>in Vitro</i> Model of Angiogenesis," <i>Am J Pathol</i> 156:1887-1900 (2000)	
CY	10	Liu, et al., "Edg-1, the G protein-coupled receptor for sphingosine-1, is essential for vascular maturation," <i>J Clin Invest</i> 106(8):951-961 (2000)	
CY	11	Wang, et al., "Sphingosine 1-phosphate stimulates cell migration through a G(i)-coupled cell surface receptor. Potential involvement in angiogenesis," <i>J Biol Chem</i> 274(50):35343-35350 (1999)	
CY	12	Kimura et al., "Sphingosine 1-phosphate stimulates proliferation and migration of human endothelial cells possibly through the lipid receptors, Edg-a and Edg-3," <i>Biochem J</i> 348 pt 1:71-76 (2000)	
CY	13	Boguslawski et al., "Sphingosylphosphorylcholine induces endothelial cell migration and morphogenesis," <i>Biochem Biophys Res Commun</i> 272(2):603-609 (2000)	
CY	14	Spiegel and Milstien, "Functions of a new family of sphingosine-1-phosphate receptors," <i>Biochim Biophys Acta</i> 1484(2-3):107-116 (2000)	
CY	15	Lee, et al., "Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate," <i>Cell</i> 99(3):301-312 (1999)	
CY	16	Lee et al., "Sphingosine-1-Phosphate as a Ligand for the G Protein-Coupled Receptor EDG-1," <i>Science</i> 279:1552- (1998)	
CY	17	Williams, et al., "Analysis of differential protein expression in normal and neoplastic human breast epithelial cell lines," <i>Electrophoresis</i> 19:333-343 (1998)	
CY	18	Yang, et al., "Combining SSH and cDNA microarrays for rapid identification of differentially expressed genes," <i>Nucleic Acids Res.</i> 27(6):1517-1523 (1999)	
CY	192	DeRisi, et al., "Use of a cDNA microarray to analyse gene expression patterns in human cancer," <i>Nature Genetics</i> 14:457-460 (1996)	
CY	20	Welford, et al., "Detection of differentially expressed genes in primary tumor tissues using representational differences analysis coupled to microarray hybridization," <i>Nucleic Acids Res.</i> 26(12):3059-3065 (1998)	
CY	21	Kahn et al., "Expression profiling in cancer using cDNA microarrays," <i>Electrophoresis</i> 20:223-229 (1999)	
EXAMINER		DATE CONSIDERED	
Chrisoph H E		5.14.03	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[illegible]

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

8085 1449A.FRM (8/95) 1038526



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **1** of **2****Complete if Known**

Application Number	09/637,977
Filing Date	August 11, 2000
First Named Inventor	Murray, Richard, et. al.
Art Unit	1642
Examiner Name	Christopher H. Yaen
Attorney Docket Number	018501-006510US

**U.S. PATENT DOCUMENTS**

Examiner	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
CY	30	PCT	WO95/29185	✓	11/02/1995	Sugen, Inc.; Max-Planck-Gesel.		<input type="checkbox"/>
CY	31	PCT	WO96/11275	✓	04/18/1996	Helsinki Univ.		<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
	A							<input type="checkbox"/>

Examiner  
Signature


Christopher H. Yaen

Date  
Considered

5.14.03

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231  
SF 1424995 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2**Complete if Known**

Application Number	09/637,977
Filing Date	August 11, 2000
First Named Inventor	Murray, Richard, et. al.
Art Unit	1642
Examiner Name	Christopher H. Yaen
Attorney Docket Number	018501-006510US

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CV	32	Tamagnone, L., et al., "BMX, a novel nonreceptor tyrosine kinase gene of the BTK/ITK/TEC/TXK family located in chromosome Xp22.2," <u>Oncogene</u> (1994) 9: 3683-3688	

Examiner  
SignatureDate  
Considered

5.14.03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
SF 1424995 v1

# INFORMATION DISCLOSURE CITATION

PTO-1449

AUG 30 2001


ATTY. DOCKET NO.  
A-68110-1/DJB/JJDSERIAL NO.  
09/637,977APPLICANT  
MURRAY, RichardFILING DATE  
August 11, 2000GROUP  
1646 1642

TECH CENTER 1600/2900

SEP 04 2000

FILING DATE

RECEIVED



## U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		PATENT NO.	DATE	NAME	CLASS	SUBCLASS	

## FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS		PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							Yes	No
CY	22	94/11499	05/1994	WO ✓				
CY	23	99/38998	08/1999	WO ✓				
CY	24	99/17796	04/1999	WO ✓				
CY	25	98/51326	11/1998	WO ✓				
CY	26	97/34920	09/1997	WO ✓				
CY	27	98/29552	07/1998	WO (EP 0 960 938 A1) ✓			X (EP)	
CY	28	99/11794	03/1999	WO ✓				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CY	29	NEZU et al., "Identification of Two Novel Human Putative Serine/Threonine Kinases, VRK1 and VRK2, with Structural Similarity to Vaccinia Virus B1R Kinase," <i>Genomics</i> 45:327-331 (1997)					

EXAMINER

Chris Lp L HX

DATE CONSIDERED

5.14.03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

8085 1449A.FRM (8/95) 1060941